Apps

オプションチェーンは、Digital Turbineの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Digital Turbineの市場センチメントを評価します。.

Digital Turbine (NASDAQ:APPS) 株価情報, オプションチェーン

Digital Turbine

Digital Turbine Inc is an independent mobile growth platform. It offers end-to-end products and solutions to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. Its operating segments are On Device Solutions and App Growth Platform.

Digital Turbine Inc

APPSOFT TECHNOLOGIES INC by AppSoft Technologies, Inc.

AppSoft Technologies Inc

AppSwarm Inc

Goldman Sachs analyst Duffy Fischer maintains PPG Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>) with a Buy and lowers the price target from $153 to $135.

News

Price Target

Analyst Ratings

Goldman Sachs Maintains Buy on PPG Indus, Lowers Price Target to $135

Contracts

ConocoPhillips Expects Most Of $2B Divestiture To Occur In 2025

JP Morgan analyst Anupam Rama maintains ORIC Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORIC#NASDAQ">ORIC</a>) with a Overweight and raises the price target from $19 to $21.

ORIC

JP Morgan Maintains Overweight on ORIC Pharmaceuticals, Raises Price Target to $21

Glen Burnie Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBZ#NASDAQ">GLBZ</a>) reported quarterly losses of $(0.01) per share. This is a 116.67 percent decrease over earnings of $0.06 per share from the same period last year.

Earnings

GLBZ

Glen Burnie Bancorp Q4 EPS $(0.01) Down From $0.06 YoY

Goldman Sachs analyst Brian Lee maintains Mueller Water Products (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MWA#NYSE">MWA</a>) with a Neutral and raises the price target from $26 to $29.

Goldman Sachs Maintains Neutral on Mueller Water Products, Raises Price Target to $29

Lytus Healthcare launched to transform patient care in India
Company positioned to build on revenue growth momentum
Secures strategic financing to fuel next-generation technology expansion
Mumbai, India, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Lytus Technologies Holdings, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYT#NASDAQ">LYT</a>), a leader in platform services and next-generation technology, is strengthening its position in the high-growth HealthTech sector through Lytus Healthcare, its fully owned subsidiary that is dedicated to revolutionizing patient care and healthcare accessibility in India.
With India's healthcare sector projected to grow at a 22% CAGR, Lytus Healthcare aims to bridge critical gaps in service delivery by integrating AI-driven patient management solutions with personalized, technology-enabled care pathways. The initiative aligns with Lytus' broader strategy of leveraging digital innovation to enhance essential services across its growing subscriber base of over 4 million users.
Building Momentum through Strategic Expansion
Lytus recently reported 26% revenue growth for the first half of FY2025, reflecting increased adoption of its digital platform services and strategic expansion efforts. The company continues to strengthen its portfolio across fintech, AI, and digital services while exploring new markets and revenue streams.
"Our strong revenue growth is a testament to Lytus' ability to execute on its vision and seize market opportunities," added Pandya. "We are committed to sustainable growth while investing in next-generation solutions that enhance both customer experience and shareholder value."
Strategic Financing to Support Expansion
To support its expansion initiatives, Lytus has entered into a Standby Equity Purchase Agreement (SEPA). Under this agreement, Lytus has access up to $100 million to deploy in its businesses as growth capital over the next three years.
An initial $6 million in funding has already been secured under the SEPA, providing Lytus with the flexibility to scale operations, expand its digital ecosystem, and advance HealthTech innovations.
"This financing enhances our ability to invest in high-growth sectors while maintaining operational agility," Pandya noted. "As we build on our technology-driven approach, we remain focused on creating long-term value for our shareholders and stakeholders."

Biotech

Global

General

Lytus Healthcare Launched To Transform Patient Care In India; Reports 26% Revenue Growth In H1 FY2025; Secures $6M Funding Under $100M SEPA To Deploy In Its Businesses As Growth Capital Over The Next 3-Years For Strategic Growth In HealthTech And Digital Services.

Benchmark analyst David Williams maintains Alpha &amp; Omega (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AOSL#NASDAQ">AOSL</a>) with a Buy and raises the price target from $40 to $42.

AOSL

Benchmark Maintains Buy on Alpha & Omega, Raises Price Target to $42

JP Morgan analyst Doug Anmuth maintains Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) with a Overweight and lowers the price target from $95 to $90.

UBER

JP Morgan Maintains Overweight on Uber Technologies, Lowers Price Target to $90

Goldman Sachs analyst Leah Jordan maintains Mondelez International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>) with a Buy and lowers the price target from $68 to $60.

MDLZ

Goldman Sachs Maintains Buy on Mondelez International, Lowers Price Target to $60

Goldman Sachs analyst James Yaro maintains Moelis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MC#NYSE">MC</a>) with a Neutral and raises the price target from $79 to $87.

Goldman Sachs Maintains Neutral on Moelis, Raises Price Target to $87

JP Morgan analyst Stephen Tusa maintains Johnson Controls Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>) with a Overweight and raises the price target from $87 to $100.

JP Morgan Maintains Overweight on Johnson Controls Intl, Raises Price Target to $100

Needham analyst Serge Belanger reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Buy and maintains $72 price target.

Reiteration

CYTK

Needham Reiterates Buy on Cytokinetics, Maintains $72 Price Target

Goldman Sachs analyst Toshiya Hari maintains Impinj (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PI#NASDAQ">PI</a>) with a Neutral and lowers the price target from $200 to $132.

Goldman Sachs Maintains Neutral on Impinj, Lowers Price Target to $132

JP Morgan analyst Alexei Gogolev maintains GoDaddy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDDY#NYSE">GDDY</a>) with a Overweight and raises the price target from $224 to $231.

GDDY

JP Morgan Maintains Overweight on GoDaddy, Raises Price Target to $231

Goldman Sachs analyst Christine Cho maintains Cheesecake Factory (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAKE#NASDAQ">CAKE</a>) with a Buy and raises the price target from $56 to $64.

CAKE

Goldman Sachs Maintains Buy on Cheesecake Factory, Raises Price Target to $64

Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) with a Buy and maintains $11 price target.

RXRX

Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $11 Price Target

JP Morgan analyst Mark Strouse upgrades Altus Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPS#NYSE">AMPS</a>) from Underweight to Neutral and announces $5 price target.

Upgrades

AMPS

JP Morgan Upgrades Altus Power to Neutral, Announces $5 Price Target

Benchmark analyst Cody Acree reiterates ARM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) from Hold to Hold.

Benchmark Reiterates Hold on ARM Holdingsto Hold

Raymond James analyst Steven Seedhouse maintains Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) with a Strong Buy and raises the price target from $122 to $125.

VKTX

Raymond James Maintains Strong Buy on Viking Therapeutics, Raises Price Target to $125

Needham analyst David Saxon reiterates Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) from Hold to Hold.

GMED

Needham Reiterates Hold on Globus Medicalto Hold

Consensus for FY25 revenue is $477.05M. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try N...

Digital Turbine raises FY25 revenue view to $485M-$490M from $475M-$485M

Digital Turbine projects nearly 50% EBITDA growth for Q4 2025 amid strong international on-device performance

Digital Turbine, Inc. (APPS) Q3 2025 Earnings Call Transcript

Digital Turbine Inc. ( ($APPS) ) has released its Q3 earnings. Here is a breakdown of the information Digital Turbine Inc. presented to its investo...

Digital Turbine Inc. Reports Challenging Quarter

Digital Turbine Q3 Earnings: Why I'm Still Not Fully Convinced

Biggest stock movers Thursday: QCOM, F, and more

Digital Turbine stock soars after annual outlook raise

Biggest stock movers Thursday: QCOM, F, RBLX, and more

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Qualcomm (QCOM) reported better-than-e...

Qualcomm, Eli Lilly report quarterly earnings beats: Morning Buzz

Pre-Market Briefing: Feb 6 – Top trade setups using our 4-pillar strategy! $ASTS leads the way, $PBI gears up for earnings, and $PTON & $APPS ride post-earnings momentum.

Market Movers: $ASTS Surges Again, $PBI Gears Up For Earnings!

AAPL

AMSC

AMZN

APPS

ARBE

ASTS

LSPD

MTCH

PSFE

PTON

QCOM

RBLX

RDDT

SONO

SWKS

Small Cap

Press Releases

Digital Turbine to Host Fiscal 2025 First Quarter Financial Results Conference Call on August 7, 2024, at 4:30pm ET

Digital Turbine Reports Fiscal 2025 First Quarter Financial Results

Entertainment

New Report Reveals The Transformative Power of Interactivity in Mobile Video Advertising

Digital Turbine to Host Fiscal 2025 Second Quarter Financial Results Conference Call on November 6, 2024, at 6:00pm ET

Digital Turbine and ONE Store Expand Partnership to Globalize Alternative App Growth

ONE Store Partners with Digital Turbine for Global App Market Expansion

Digital Turbine Reports Fiscal 2025 Second Quarter Financial Results

TIM and Digital Turbine Announce Partnership to Enhance Mobile User Experience in Brazil

Digital Turbine to Host Fiscal 2025 Third Quarter Financial Results Conference Call on February 5, 2025, at 4:30pm ET

Digital Turbine Reports Fiscal 2025 Third Quarter Financial Results

AudioEye

Arqit Quantum

Bit Digital

CoreCard

Domo

Viant Technology

eGain

Expensify

Gorilla Technology Group Inc. - Ordinary shares

Gorilla Tech Gr

Helport AI

Kaltura

CS Disco

The9 Limited - American Depository Shares

The9

Nvni Group

ON24

Ooma

Perfect

Radcom

Rekor Systems

Rimini Street

SoundThinking

ReposiTrak

Veritone

Xunlei Limited - American Depositary Shares

Xunlei

B of A Securities

Macquarie

Craig-Hallum

Roth MKM

B. Riley Securities

WIIM

Digital Turbine shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance.

Comments

Digital Turbine

Digital Turbine (APPS) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル